RxDoctor Payments Data

Eva Tsalikian

Pediatric Endocrinology · Iowa City, IANPI 1619963949

Payments from drug & device makers

What this record shows

The money is spread across several categories — consulting fees (43.5%), education and food and beverage — rather than concentrated in one kind of arrangement. 3 manufacturers reported payments, led by Pfizer at 43.5% of the total.

$230in general payments, 2019–2025

Across 5 payments — averaging $46.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$100
  • Novo Nordisk$97
  • Biomarin Pharmaceutical Inc.$33
$956,929in research payments, 2019–2025

Across 598 payments — averaging $1600.22 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Boehringer Ingelheim$304K
  • Takeda Pharmaceuticals U.S.A., Inc.$170K
  • Novo Nordisk AS$130K
  • OPKO Pharmaceuticals, LLC$93K
  • Abbott$64K
  • Astrazeneca UK Limited$58K
  • plus $138K from 6 others

What the payments were for

  • Consulting fees$10043%
  • Food & beverage$3314%
  • Education$9742%

General payments by program year

20
21

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Pfizer1$100
Novo Nordisk3$97
Biomarin Pharmaceutical Inc.1$33

How this compares

Too few pediatric endocrinology providers in Iowato place this figure against a meaningful peer group, so we don't.

Other pediatric endocrinology in Iowa City

See the full list for Iowa →

Where these figures come from

Is this you, or does something look wrong? →